Loading news...
TOKYO & NEW YORK & DÜSSELDORF, Germany--(BUSINESS WIRE)--Asahi Kasei Microdevices Corporation and Silicon Austria Labs GmbH, have successfully completed a joint proof of concept of the eFuse technology.
MorphoSys AG (NASDAQ:MOR – Free Report) – Stock analysts at Leerink Partnrs raised their Q2 2024 EPS estimates for MorphoSys in a research report issued to clients and investors on Wednesday, May 15th. Leerink Partnrs analyst A. Berens now expects that the company will post earnings of ($0.54) per share for the quarter, up from their prior forecast of ($0.56). The consensus estimate for MorphoSys’ current full-year earnings is ($2.43) per share. Leerink Partnrs also issued estimates for MorphoSys’ Q3 2024 earnings at ($0.43) EPS, Q4 2024 earnings at ($0.41) EPS, FY2024 earnings at ($2.76) EPS, FY2025 earnings at ($1.82) EPS, FY2026 earnings at ($1.27) EPS and FY2027 earnings at ($1.26) EPS. MorphoSys (NASDAQ:MOR – Get Free Report) last issued its quarterly earnings results on Monday, April 29th. The company reported ($2.24) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.51) by ($1.73). The business had revenue of $29.86 million for the quarter, compared to analyst estimates of $48.99 million. MorphoSys had a negative return on equity of 694.31% and a negative net margin of 226.79%. Separately, Wells Fargo & Company reissued an “equal weight” rating and issued a $18.25 target price (up from $17.00) on shares of MorphoSys in a research report on Thursday, March 14th. Five research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $11.78. Check Out Our Latest Stock Analysis on MOR MorphoSys Price Performance NASDAQ MOR opened at $19.00 on Monday. The company has a debt-to-equity ratio of 4.98, a current ratio of 1.38 and a quick ratio of 1.38. The stock’s fifty day moving average price is $18.07 and its 200 day moving average price is $13.45. MorphoSys has a 1 year low of $4.18 and a 1 year high of $19.50. The company has a market cap of $2.86 billion, a price-to-earnings ratio of -5.46 and a beta of 1.15. Institutional Investors Weigh In On MorphoSys Several hedge funds have recently added to or reduced their stakes in the business. Carlson Capital L P purchased a new stake in MorphoSys in the first quarter valued at $17,241,000. Henry James International Management Inc. boosted its holdings in MorphoSys by 105.8% in the first quarter. Henry James International Management Inc. now owns 88,506 shares of the company’s stock valued at $1,605,000 after purchasing an additional 45,506 shares during the last quarter. SAL Trading LLC purchased a new stake in MorphoSys in the first quarter valued at $486,000. Susquehanna International Group Ltd. purchased a new stake in MorphoSys in the first quarter valued at $1,333,000. Finally, BNP Paribas Financial Markets boosted its holdings in MorphoSys by 130.4% in the first quarter. BNP Paribas Financial Markets now owns 32,533 shares of the company’s stock valued at $590,000 after purchasing an additional 18,413 shares during the last quarter. 18.38% of the stock is owned by hedge funds and other institutional investors. About MorphoSys (Get Free Report) MorphoSys AG, together with its subsidiaries, engages in the development and commercialization of therapeutics for patients suffering from various cancers in Europe, Asia, and the United States. The company's product pipeline includes Pelabresib that is in Phase 3 trials to treat myelofibrosis and thrombocythemia; Tulmimetostat, a product candidate in Phase 1/2 trials for the treatment of solid tumors and lymphomas; Felzartamab, an antibody directed against CD38 for renal autoimmune diseases and relapsed/refractory multiple myeloma; Ianalumab, a candidate in Phase 3 clinical trials for Sjögren's disease, lupus nephritis, and other autoimmune diseases; Abelacimab that is in Phase 3 trials for venous thromboembolism prevention and cancer-associated thrombosis; Setrusumab, which is in Phase 2/3 trials for osteogenesis imperfecta; and Bimagrumab, a product candidate in Phase 2b trials for adult obesity.
LAKEVILLE, Conn., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Salisbury Bancorp, Inc. (“Salisbury”), (NASDAQ Capital Market: “SAL”), the holding company for Salisbury Bank and Trust Company (“Salisbury Bank”), announced that it completed its merger with and into NBT Bancorp Inc. (“NBT”) (NASDAQ: NBTB) (the “Merger”) on August 11, 2023.
LAKEVILLE, Conn., July 26, 2023 (GLOBE NEWSWIRE) -- Salisbury Bancorp, Inc. (“Salisbury”), (NASDAQ Capital Market: “SAL”), the holding company for Salisbury Bank and Trust Company (the “Bank”), announced results for its second quarter ended June 30, 2023.
Salisbury Bancorp (SAL) came out with quarterly earnings of $0.60 per share, missing the Zacks Consensus Estimate of $0.82 per share. This compares to earnings of $0.62 per share a year ago.
Salisbury Bancorp (SAL) delivered earnings and revenue surprises of 9.23% and 4.36%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Salisbury Bancorp (SAL) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Salisbury Bancorp (SAL) delivered earnings and revenue surprises of -2.60% and 1.11%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Salisbury Bancorp (SAL) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Salisbury Bancorp (SAL) delivered earnings and revenue surprises of -8.33% and 2.67%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Salisbury Bancorp (SAL) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Salisbury Bancorp (SAL) delivered earnings and revenue surprises of -15.75% and 2.90%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Salisbury Bancorp (SAL) have what it takes?
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Salisbury Bancorp (SAL) have what it takes?
Salisbury Bancorp (SAL) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Salisbury Bancorp (SAL) have what it takes?
If you are looking for stocks that are well positioned to maintain their recent uptrend, Salisbury Bancorp (SAL) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Salisbury Bancorp (SAL) have what it takes?